Page 85 - Haematologica August 2018

Haplo versus MSD in AML in CR1
39% versus 33% (P=0.79). The probability of LFS and OS were 61 % versus 55% (P=0.14) and 67% versus 66% (P=0.26) in Haplo and MSD, respectively. Probability of GRFS was 49% versus 40% (P=0.17), in Haplo and MSD, respectively. CI of relapse was 21% versus 36% (P<0.02) and NRM was 18% versus 10% (P=0.16) for Haplo and MSD, respectively.
In multivariate analysis, Haplo was associated with a higher risk of grade II-IV aGvHD (HR 2.20; 95% CI 1.29- 3.74; P<0.01) and a trend for a lower RI (HR 0.56; 95% CI 0.31-1.01; P=0.06). No significant differences were found for other outcomes. Results of multivariate analysis for donor type and other factors associated with the main outcomes are reported in table 3C.
AB
CD
Figure 1. Outcomes at two years according to pair-matched analysis in patients with intermediate-risk acute myeloid leukemia. (A) Relapse-incidence. (B) Non- relapse mortality. (C Leukemia-free survival. (D) Overall survival.
Figure 2. Outcomes at two years according to pair-matched analysis in patients with high-risk acute myeloid leukemia. (A) Relapse-incidence. (B) Non-relapse mor- tality. (C) Leukemia-free survival. (D) Overall survival.
AB
CD
haematologica | 2018; 103(8)
1321